CYC-116
- Soluble in DMSO
- MF: C18H20N6OS
- MW: 368.46
Description
An orally-active inhibitor of Aurora kinases A and B, and VEGFR2.
More Information
| Parent CAS No. | 693228-63-6 |
|---|---|
| Chemical Name | 4-Methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | C1C(C2=C(C)N=C(N)S2)=NC(NC2C=CC(N3CCOCC3)=CC=2)=NC=1 |
| MFCD | N.A. |
| InChi | InChI=1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23) |
| InChiKey | GPSZYOIFQZPWEJ-UHFFFAOYSA-N |
| CID | 6420138 |
| Short Description | Aurora kinases A & B and VEGFR2 inhibitor |
References
- S Wang et al. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10;53(11):4367-78.
- D MacCallum, David et al. Combination of CNDAC with a 2-substituted-4-heteroaryl-pyrimidine amine and use thereof in the treatment of a proliferative disorder; 2007; WO 2007132228
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1398 | Sunitinib malate |
From $88.00 |
| 1411 | Vandetanib |
From $55.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1461 | Cediranib |
From $77.00 |
| 1540 | VX 680 |
From $66.00 |
| 1541 | ZM 447439 |
From $93.50 |
| 1547 | OSI 930 |
From $99.00 |
| 1580 | AZD1152-HQPA |
From $77.00 |
| 1597 | Aurora A inhibitor I |
From $137.50 |
| 1630 | Aurora A inhibitor II |
From $137.50 |
| 1637 | Vatalanib |
From $82.50 |
| 1638 | ABT 869 |
From $88.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1662 | CP 547632 |
From $77.00 |
| 1667 | SU 5402 |
From $66.00 |
| 1678 | Regorafenib |
From $77.00 |
| 1717 | Tivozanib |
From $88.00 |
| 1768 | AMG 706 |
From $115.50 |
| 1783 | AMG 900 |
From $121.00 |
| 1819 | Cabozantinib S-malate |
From $66.00 |
| 1836 | CCT 137690 |
From $126.50 |
| 1850 | BMS 540215 |
From $121.00 |
| 1864 | Brivanib alaninate |
From $99.00 |
